New Insight with Dr. Veeral Sheth

Don’t Miss a Beat

Crisis Point

Revolutionizing Atopic Dermatitis

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

New research highlighted the need to improve 

 scoring systems and to circulate unified diagnostic criteria for anaphylactic reactions.

“Today, depending on the used classification, it is impossible to simply state the grade of severity of an anaphylactic reaction without contextualizing it to the referred scoring method,” wrote investigators, led by Yanis Bouderbala, from the allergy unit at Hôpital Arnaud de Villeneuve, University Hospital of Montpellier, in France. “Our work underlines, therefore, the importance of disseminating and using a simple and unified global classification to improve education, clinical approaches to patients, and clear interactions between physicians.

Anaphylaxis has a clear definition: “a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death.”

 The World Allergy Organization (WAO) anaphylaxis committee proposed that the anaphylaxis diagnosis should be based on 1 of 2 criteria:

The acute onset of an illness with the involvement of the skin or mucosal tissue and associated with a respiratory compromise, reduced blood pressure, or severe gastrointestinal symptoms.

An acute onset of hypotension or bronchospasm, or laryngeal involvement, in an individual with a previous allergy and suspected exposure to this allergen.

Although anaphylaxis has a well-defined diagnostic criterion, there is still debate on classifying the severity of an anaphylactic reaction. Several classifications emerged in recent years, such as the 11th version of the International Classification of Diseases (ICD‐11), the CoFAR, Dribin, EAACI (European Academy of Allergy and Clinical Immunology), and Blazowski.

These classifications have significantly advanced anaphylaxis management, such as recommending the early use of adrenaline. However, the lack of uniformity in grading anaphylaxis severity across different classifications can lead to inconsistencies in how allergies are treated for potentially life-threatening reactions. These differences in proposed classifications consider allergic triggers, age groups, and whether the reaction occurred in a real-life exposure or a hospital iatrogenic setting.

In this recent retrospective observational monocentric study, investigators sought to evaluate possible discrepancies in the scoring system for anaphylaxis, looking at various classifications. Secondary objectives included comparing symptoms before and after a positive food challenge and assessing the effectiveness of an adrenaline injection based on the severity of symptoms; to see if adrenaline was an appropriate management, the team compared patients who did and did not experience anaphylaxis during the challenge.

The team assessed the scoring system among 235 adults and children who underwent a positive oral food challenge for an IgE-mediated food allergy between January 2018 – December 2022. Patients with a history of anaphylaxis had a prescription for Adrenaline Auto-Injector, and parents or caregivers had to bring an emergency kit with the adrenaline the day of the oral food challenge.

According to the ICD-11 classification, more than half of the sample (60.9%) suffered from anaphylaxis. Participants experiencing anaphylaxis experienced significantly more respiratory and gastrointestinal symptoms. The analysis also found that less than half of participants suffering from anaphylaxis (47.6%) received an adrenaline injection, including in a specialized setting.

“What still needs to be the cornerstone of the management of anaphylaxis is the injection of IM adrenaline, and the diagnosis of anaphylaxis should remain essentially based on a clinical assessment of the patient,” investigators wrote. “If, on one hand, the injection of adrenaline should never be delayed, regardless of the supposed severity of the anaphylactic reaction, an easy and practical overall accepted classification could help avoid the underuse of adrenaline.”

When comparing the different classifications, investigators found a complete concordance in only 8 patients (5.6%). All 5 classifications showed a good sensitivity (99.3% - 100%) but a wide-ranging specificity (67.4% - 93.5%). The study observed discrepancies in the different classifications of most patients.

“We showed that the likelihood of agreement between the different classifications is low, especially if we consider that they are based on 3–5 different grades: such discrepancy shows that the multitude of classifications doesn't help understand the severity of the reaction,” investigators wrote. “…from an educational point of view, and for a better management between teams and an easier comprehension from non‐specialized physicians…the use of an easy‐to‐understand simple and common classification would help reduce possible misunderstandings and improve the therapeutic approach towards patients.”

Bouderbala Y, Clark E, Tanno LK, Demoly P, Caimmi D. Anaphylaxis severity grade, during oral food challenges, assessed by five different classifications. Pediatr Allergy Immunol. 2025 Mar;36(3):e70065. doi: 10.1111/pai.70065. PMID: 40116239; PMCID: PMC11926947.

Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, Geller M, Gonzalez-Estrada A, Greenberger PA, Sanchez Borges M, Senna G, Sheikh A, Tanno LK, Thong BY, Turner PJ, Worm M. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J. 2020 Oct 30;13(10):100472. doi: 10.1016/j.waojou.2020.100472. PMID: 33204386; PMCID: PMC7607509.

Articles

Recent research emphasizes the need for a unified anaphylaxis classification system to improve diagnosis and management. Current classifications, such as ICD-11 and others, show significant variability, leading to inconsistencies in treatment, particularly regarding adrenaline administration. A study involving 235 patients undergoing food challenges revealed discrepancies in classification agreement, with only 5.6% concordance among five systems. Despite high sensitivity, specificity varied widely. The study advocates for a simple, universally accepted classification to enhance understanding, education, and therapeutic approaches, ensuring timely adrenaline use in anaphylaxis management.

New study highlights discrepancies in anaphylaxis severity scoring, emphasizing the need for a unified classification to improve treatment.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Study Underscores the Need to Unify Anaphylaxis Severity Scoring Systems

Mack Mitchell, MD, is the vice president for medical affairs and the Nancy and Jeremy Halbreich Professor of Internal Medicine at UT Southwestern.

Reducing Alcohol Use in Patients with Liver Disease, with Mack Mitchell, MD

 remains a critical yet underutilized component of 

While significant advances have been made in addressing the complications of advanced liver disease, there is a growing recognition that early intervention is essential for preventing disease progression. However, the stigma surrounding AUD, both within the healthcare system and society at large, frequently creates barriers to effective treatment.

A 2024 study from Massachusetts General Hospital found that although practice recommendations from several medical societies advise against potentially stigmatizing language for AUD and ALD, many liver transplant centers continue to use outdated terms like “alcoholism” and “alcoholic,” potentially hindering patient care and their willingness to seek treatment.

Overcoming challenges like this will require a shift in perspective, recognizing AUD as a treatable medical condition and integrating evidence-based interventions into routine hepatology care.

, Mack Mitchell, MD, vice president for medical affairs and the Nancy and Jeremy Halbreich Professor of Internal Medicine at UT Southwestern, reviews pharmacologic treatment options for AUD in patients with ALD and looks ahead to other medications that may eventually be used in these patients.

Mitchell begins by highlighting the 3 medications that are currently approved by the FDA to reduce drinking: disulfiram, naltrexone, and acamprosate. However, he notes that disulfiram is not suitable for use in patients with liver disease due to its off-target side effects.

Of the remaining therapies, Mitchell says clinicians should consider acamprosate for their patients who have a longer drinking history and disulfiram for patients in earlier stages of AUD.

Looking ahead, Mitchell says he believes GLP-1 receptor agonists will eventually be used for patients with AUD and ALD, citing recent research demonstrating use of semaglutide led to reduced alcohol consumption. Similarly, he says he thinks resmetirom (Rezdiffra), which is currently approved by the FDA for the treatment of patients with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), will be used for the treatment of AUD and ALD.

“I think the landscape out there is pretty exciting,” Mitchell concluded. “Hopefully, over the next 5 to 10 years, we will see a lot better outcomes in all of the patients with steatotic liver disease.”

Managing Alcohol Use Disorder in Alcohol-Associated Liver Disease, with Mack Mitchell, MD

Editors’ note: Mitchell has relevant disclosures with Durect, GlaxoSmithKline, and National Institute on Alcohol Abuse and Alcoholism.

Brooks A. The Power of Words: Liver Transplant Centers Continue to Use Stigmatizing Language. HCPLive. February 17, 2024. Accessed March 24, 2025. 

https://www.hcplive.com/view/the-power-words-liver-transplant-centers-continue-use-stigmatizing-language

Brooks A. Resmetirom (Rezdiffra) Receives Historic FDA Approval for Noncirrhotic NASH. HCPLive. March 14, 2024. Accessed March 24, 2025. 

https://www.hcplive.com/view/resmetirom-rezdiffra-receives-historic-fda-approval-for-noncirrhotic-nash

Videos

Mitchell reviews FDA-approved drugs for reducing alcohol use, which ones can be used in patients with liver disease, and other therapies on the horizon.

Hepatology

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Ferric carboxymaltose may improve hemoglobin and ferritin levels in people with underlying iron deficiency 

 (IDA) over iron sucrose, according to a new review and meta-analysis of randomized controlled trials.

“This systematic review and meta-analysis provide a potential advantage of FCM over IS in improving hemoglobin and ferritin levels, particularly among patients with gynecological disorders underlying IDA. While both iron preparations demonstrated comparable efficacy in the general population, the findings underscore the importance of considering the specific etiology of anemia when choosing between these treatments,” lead investigator Lokman H Tanrıverdi, İnönü University Faculty of Medicine, Department of Medical Pharmacology, Malatya, Turkey, and colleagues wrote.

Tanrıverdi and colleagues conducted a systematic literature search across PubMed, Ovid Medline, Web of Science, Scopus, and the Cochrane Library up to Jan 1, 2024, and identified trials directly comparing FCM and IS treatments in adult patients with IDA. They conducted meta-analyses with inverse variance random effects models to determine the primary outcome of change in hemoglobin levels during follow-up.

“Previous randomized controlled trials have examined the comparative efficacy and safety of FCM and IS, particularly in the treatment of anemia in various populations. However, the using of FCM and IS in different patient populations and clinical contexts has shown varying efficacy and safety results

The analysis included 14 trials with a total of 4757 patients. The investigators found that FCM resulted in a nonsignificant increase in hemoglobin levels (mean difference [MD], 0.45 g/dL; 95% CI, 0.08-0.83; 

= .02) and ferritin levels (MD, 37.32 ng/mL; 95% CI, 18.98-55.65; 

Additionally, they found that FCM was associated with a higher risk of hypersensitivity reactions compared to IS (relative risk [RR], 2.97; 95% CI: 1.35-6.52, 

<.01) but not with severe adverse events (AE; RR, 1.03; 95% CI, 0.88-1.21; 

= .70). They also found a nonsignificant increased risk of hypophosphatemia (RR, 2.84; 95% CI, 0.89-9.06; 

The investigators also looked at FCM’s efficacy stratified by subgroups and found that FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia (MD, 1.04 g/dL; 95% CI, 0.75-1.33; 

 <.01) but was statistically less effective for patients with hemodialysis (MD, -0.24 g/dL; 95% CI, -0.53-0.04; 

“Ten studies showed some concerns of risk of bias, and four studies had a high risk of bias for the change in hemoglobin levels during follow-up. Lack of standardized definitions for hypersensitivity reactions and variability in dosing protocols and follow-up durations across studies may affect the generalizability of our safety findings,” Tanrıverdi and colleagues wrote.

The investigators used a graphical funnel plot to evaluate bias. They noted limitations of the study, including a lack of reported data on key safety outcomes, such as hypophosphatemia, as well as standardized definitions for serious or severe AEs or hypersensitivity, which may limit the generalizability of their findings. Other variability in factors across studies may also have influenced the observed treatment effects.

Tanriverdi LH, Sarici A. Efficacy, Safety, and Tolerability of Ferric Carboxymaltose and Iron Sucrose in Iron Deficiency Anemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. 

. Published online March 17, 2025. doi:10.4274/tjh.galenos.2025.2025.0034

Shin HW, Go DY, Lee SW, Choi YJ, Ko EJ, You HS, Jang YK. Comparative efficacy and safety of intravenous ferric carboxymaltose and iron sucrose for iron deficiency anemia in obstetric and gynecologic patients: A systematic review and meta-analysis. 

A recent systematic review and meta-analysis compared ferric carboxymaltose (FCM) and iron sucrose (IS) in treating iron deficiency anemia (IDA). FCM showed a nonsignificant improvement in hemoglobin and ferritin levels over IS, particularly in patients with gynecological disorders. However, FCM was linked to a higher risk of hypersensitivity reactions. The study highlighted the importance of considering anemia's etiology when selecting treatments. Limitations included potential bias, lack of standardized definitions for hypersensitivity, and variability in dosing protocols, affecting the generalizability of safety findings.

FCM yielded a statistically significant improvement in Hb levels in patients with postpartum anemia over IS.

Anemia

Hematology

Ferric Carboxymaltose May Improve Outcomes For Subgroups of Iron Deficiency Anemia

Sumitra Khandelwal, MD is a professor of ophthalmology at the Cullen Eye Insitute at Baylor College of Medicine, and medical director for the Lions Eye Bank of Texas.

Evolution of IOL Technology with Sumitra Khandelwal, MD

As cataract surgery continues to evolve, advancements in intraocular lens (IOL) technology and preoperative diagnostics are reshaping patient outcomes. Balancing cutting-edge technology with established methods is key in IOL selection.

, Sumitra Khandelwal, MD, a professor of ophthalmology at the Cullen Eye Insitute at Baylor College of Medicine, and medical director for the Lions Eye Bank of Texas, explained how each lens category continues to evolve, with newer options offering distinct advantages and trade-offs.

Khandelwal recently presented a session titled “Pearls for Picking the Perfect IOL” at the 

Texas Ophthalmological Association (TOA) Annual Meeting

Khandelwal noted that while mono-focal lenses remain the most common choice, advancements in trifocal and astigmatism-correcting IOLs allow for greater spectacle independence—though some patients may experience glare and halos.

She indicated one of the most innovative options available is the light-adjustable lens, which allows post-surgical customization over multiple visits. While offering precise visual outcomes, Khandelwal emphasized the need for patient commitment due to the time-intensive nature of adjustments. This option could be particularly beneficial for those uncertain about monovision, as it allows for refinements after surgery.

Khandelwal also highlighted the evolving role of ocular surface disease management in optimizing cataract surgery outcomes. With an increasing number of pharmaceutical treatments—ranging from anti-inflammatory drops to tear stimulators—the field is experiencing rapid expansion. She noted that understanding how to integrate these treatments effectively will be a key focus in ophthalmology throughout the year.

Khandelwal reports disclosures with Alcon, Bausch + Lomb, Dompe, Ocular Therapeutix, and others.

Repka MX. Pearls for Picking the Perfect IOL. Presented at Texas Ophthalmological Association (TOA) Annual Meeting. Houston, Texas. March 21-22, 2025

Chandra S, Sivaprasad S, Ursell PG, et al. Recurring themes during cataract assessment and surgery. Eye (Lond). 2021;35(9):2482-2498. doi:10.1038/s41433-021-01548-4

Khandelwal discusses advancements in intraocular lens (IOL) categories and the patient's role in choosing more innovative options.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Family Medicine

Family Medicine condition center page, resources on the topics of medical news and expert insight into family care can be found. Content includes articles, interviews, videos, podcasts, and breaking news on Family medicine research, treatment, and drug development.

Hospital Medicine

The HCPLive hospital medicine page is a comprehensive resource for clinical news and insights on the emergency medicine specialty. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for emergent care, and more.

Exploring the Evolution of IOL Technology with Sumitra Khandelwal, MD

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

While tildrakizumab’s efficacy and safety have been confirmed among clinicians and among patients with 

, new findings suggest some patients continue to be dissatisfied despite solid disease control.

These data represent the conclusion of an analysis conducted by a team of investigators, 1 of which was Ziad Reguiai, from the Department of Dermatology at the Polyclinique Courlancy in Reims-Bezannes, France. Reguiai et al. highlighted that prior real-world data on tildrakizumab use for psoriasis had been primarily from clinicians’ perspectives.

In France, the Observatory of Chronic Inflammatory Skin Diseases (OMCCI) register was initiated with the aim of prospectively assessing patients’ long-term impairments resulting from chronic 

 In this study, data on patients with moderate-to-severe psoriasis given tildrakizumab were assessed 1 year following their inclusion in the OMCCI register.

“We aimed to analyze the efficacy and safety of tildrakizumab in a real-life setting, and to describe the impact of psoriasis and its treatment both globally and in some more specific locations from the patient's perspective in the long term,” Reguiai and colleagues wrote.

Real-World Analysis of Tildrakizumab for Psoriasis

The investigative team presented findings from a set of 3 key points in time, looking at patients included in the aforementioned OMCCI registry. Those in this register are scheduled for follow-up over a 4-year timeframe, with annual evaluations carried out by clinicians and bi-annual self-reported data collection. The 3 key time points from which they drew this data were baseline (initiation of treatment), the 6-month mark, and 12 months post-initiation.

The team involved individuals being treated with routine care for moderate-to-severe psoriasis consecutively at the time of their treatment initiation. The medication was administered under real-world conditions using the standard  regimen for dosing: 100 mg per injection for those weighing less than 90 kg, and 200 mg for patients exceeding 90 kg or reporting a high level of disease burden. There was not a washout period mandated prior to starting tildrakizumab at the inclusion visit.

The Psoriasis Area and Severity Index (PASI) was used to assess disease severity levels, with a range of scores from 0 - 72. In general, the investigators gathered patient information via standardized forms capturing age during diagnoses, sociodemographic data, records of hospitalizations, sick leave within the past 6 months, consultations with specialists, and adherence to tildrakizumab.

Short questionnaires were provided to participants every 6 months, with assessments including the Dermatology Life Quality Index (DLQI). They looked at health-related quality of life through the 12-Item Short-Form Health Survey (SF-12), with 2 composite scores: physical and mental. Additionally, they implemented an Individual Burden of Psoriasis (I-BOP) survey for participants to assess the multidimensional impact of the disease.

Additionally, the Simplified Index Psoriasis (Sa-SPI) self-evaluation was required among trial participants, with ratings highlighting disease effects on family life, daily activities, and professional life over the week prior to enrollment via a Numerical Rating Scale (NRS) from 0 - 10 (where 0 = "my skin condition does not bother me at all," 5 = "moderately bothersome," and 10 = "extremely bothersome, I cannot imagine anything worse").

An overall evaluation was also provided by subjects regarding how psoriasis impacts daily life, with selections including a complete lack of impact, minor life impairment, moderate impairment, or a severe level of impairment that prevents typical daily activities.

The investigative team could choose from 4 predefined categories to highlight rationale for discontinuation of tildrakizumab: a lack of treatment efficacy, adverse effects, decisions among patients, or other (without specifying details). Additionally, they only documented serious adverse events or those leading to cessation.

In terms of quantitative variables assessed by the research team, their analyses included the mean, the number of non-missing values, standard deviation, and 95% confidence interval (CI) where applicable. They also reported qualitative variables as frequencies and percentages.

Overall, psoriasis at baseline was shown in the team's findings to have significantly impaired the lives of study subjects. Specifically, they noted that 42% showed signs of clinical depression and added that 34.6% reported disease involvement in the genital region that led to negative impacts in their sexual well-being.

Following the 1-year mark, the investigators concluded that tildrakizumab demonstrated overall safety and efficacy among patients, and they noted this  included efficacy in regions of the body deemed challenging-to-treat. There was also a decline in PASI score from 13.6 to 2.3, and the team further noted that an increase in the SF-12 mental component score was observed from 41 to 48.7.

The analysis further highlighted DLQI improvements from 10.4 to 2.5. Despite such gains, it was noted that some participants remained dissatisfied. This dissatisfaction was noted along with a citation of concerns about psoriasis relapse and the persistent mental health burden linked to the inflammatory disease in the long term.

"Psoriasis is a complex disease from the point of view of its pathophysiology, which involves tissue-resident memory T cells (TRM) that perpetuate the disease and its relapses," the investigators concluded. "It is also a complex pathology when we consider the psychology of our patients."

Reguiai, Z., Becherel, P.A., Maccari, F, et al. (2025). Patient's Perspective on the Impact of Psoriasis on Their Quality of Life After 1 Year of Tildrakizumab Treatment: Despite Clinical Improvement, Persistence of a Potential Mental Cicatricial Memory of the Disease. JEADV Clinical Practice. 

P. A. Becherel, Z. Reguiai, A. C. Fougerousse, et al., “Compared Burden of Psoriasis, Atopic Dermatitis, Hidradenitis Suppurativa, and Chronic Urticaria: Baseline Characteristics of the Patients Included in the OMCCI Cohort - A French, Prospective Multicenter Study of Chronic Inflammatory Dermatoses,” Dermatology Published ahead of print, (2024), 

Tildrakizumab has shown efficacy and safety in treating moderate-to-severe psoriasis, yet some patients remain dissatisfied despite disease control. A study from the OMCCI register in France assessed patients' long-term experiences with tildrakizumab, focusing on real-world outcomes. The study found significant improvements in PASI scores and quality of life measures, but some patients still experienced dissatisfaction due to concerns about relapse and mental health burdens. The complexity of psoriasis, involving both pathophysiological and psychological factors, contributes to these persistent challenges.

In this analysis, French investigators highlight patient and clinician perspectives on 1-year use of tildrakizumab for moderate-to-severe psoriasis.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Tildrakizumab Effective for Psoriasis, Yet Patients Note Specific Points of Dissatisfaction

Michael Schilsky, MD, is a professor of medicine and medical director of adult liver transplant at Yale-New Haven Transplantation Center.

Schilsky describes lingering challenges and unmet needs in Wilson disease and highlights recent innovations in monitoring and diagnosis.

Challenges and Innovations in Wilson Disease, with Michael Schilsky, MD

Khandelwal shares insight and key takeaways for the optimization of intraocular lens selection in practice.

Clinical Pearls for Choosing the Right IOL with Sumitra Khandelwal, MD

A new study found that the time it takes to diagnose alpha-gal syndrome has improved from 5.3 years to 28 days since 2011, but disparities remain based on education level.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Alpha-Gal Syndrome Diagnosis Time Drops 70-Fold, But Disparities Persist

Panelists discuss how establishing realistic treatment goals for patients with moderate to severe atopic dermatitis requires collaborative conversations addressing itch reduction, sleep improvement, and quality-of-life enhancement, whereas decisions to initiate systemic therapy are driven by inadequate response to optimized topical regimens, disease impact on daily functioning, recurrent flares, significant psychological burden, treatment adherence challenges, and the recognition that early intervention may prevent disease progression and comorbidities.

Video Series

Establishing Atopic Dermatitis Treatment Goals and Expectations With Patients

Panelists discuss how atopic dermatitis severity assessment involves evaluating disease extent, lesion intensity, location, symptom burden, and quality-of-life impact—with mild cases showing limited, occasionally pruritic patches; moderate cases featuring more widespread, persistent symptoms affecting daily activities; and severe cases presenting with extensive, intensely pruritic lesions causing significant sleep disturbance and emotional distress.

Assessing Atopic Dermatitis Severity in Clinical Practice

Podcasts

Veeral Sheth, MD, is joined by the CEO of Neurotech to discuss the historic approval of revakinagene taroretcel (ENCELTO) for macular telangiectasia type 2.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

New Insight with Veeral Sheth, MD

Sheth, Director of Clinical Trials at University Retina in Chicago, takes an in-depth look at the biggest news in ophthalmology and the behind the scenes work involved in eye care, with a rotation of guest experts involved in ophthalmic research, development, and clinical care.

RDR Alert®

The Rare Disease Report page is a resource for medical news and expert insights on rare diseases. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for sickle cell disease, multiple myeloma, and more.

New Insight: Exploring ENCELTO for MacTel with Rich Small, CEO of Neurotech

Michael X. Repka, MD is a Professor of Ophthalmology and Professor of Pediatrics at the Wilmer Eye Institute, Johns Hopkins University School of Medicine and the 2025 President of the American Academy of Ophthalmology.

Repka describes the complications of the US healthcare system and how to advance interactions in advocacy efforts.

Fostering Advocacy Efforts in Ophthalmology with Michael X. Repka, MD

Goel explains the importance of second-line therapies and describes the role PPARs play in PBC treatment, including 2 newly approved therapies.

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Understanding the Role of PPAR Agonists in PBC Care, with Aparna Goel, MD

Repka dives into the role of advocacy in shaping ophthalmologic policies and ensuring equitable patient care.

Examining the Role of Advocacy in Ophthalmology with Michael X. Repka, MD

Analgesic effects lasted up to week 8 while function improvements lasted until week 16 in a new randomized, controlled trial.

Fibromyalgia

On the HCPLive fibromyalgia page, resources on the topics of medical news and expert insight into fibrositis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on fibromyalgia, and more.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Latest News

Study Underscores the Need to Unify Anaphylaxis Severity Scoring Systems

Reducing Alcohol Use in Patients with Liver Disease, with Mack Mitchell, MD

Ferric Carboxymaltose May Improve Outcomes For Subgroups of Iron Deficiency Anemia

Exploring the Evolution of IOL Technology with Sumitra Khandelwal, MD

Tildrakizumab Effective for Psoriasis, Yet Patients Note Specific Points of Dissatisfaction